← SynDRA
TEMSIROLIMUS
SynDRA canonical compound SYN0023453 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | MTOR |
|---|
| Mechanism of action | MTOR inhibitor |
|---|
| Indication | renal cell carcinoma (RCC) |
|---|
| Disease area | oncology |
|---|
All known targets
- MTOR
- FKBP1A
- ABCB1
- FKBP3
- IFNAR2
- PTEN
- CCR5
- SLC28A1
- CYP3A4
- ABCG2
- CYP2C9
- CYP2C19
Mechanisms of action (all sources)
- MTOR inhibitor
- FKBP1A INHIBITOR
- FK506-binding protein 1A inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB11
- ESR1
- SYK
- PASK
- PAK6
- PAK4
- PAK2
- PAICS
- OPRM1
- OPA1
- OLA1
- PDE3A
- NUAK2
- NTRK1
- NQO2
- NLK
- NEK9
- NEK7
- NEK3
- NEK2
- PCYT1A
- PDE4A
- NDUFA13
- PIP4K2C
- PRKACA
- PRKAA1
- PLK4
- PLK1
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2A
- PDGFRB
- PIM2
- PIM1
- PHKG2
- PGRMC1
- PGR
- PFKP
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Protein Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Immunologic Factors
- Immunosuppressive Agents
- MTOR Inhibitors
- Kinase Inhibitor
- mTOR Inhibitor Immunosuppressant
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
- S01X · OTHER OPHTHALMOLOGICALS
- L04A · IMMUNOSUPPRESSANTS
Cross-references
Synonyms
- TORISEL
- Torisel
- torisel
- temsorolimus
- CCI 779
- CCI-779
- Sifalimumab
- Cci 779
- CHEBI:79699
- Torisel (TN)
- 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin
- Temsirolimus (JAN/USAN/INN)
- DB06287
- C15182
- D06068
- J-524319
- 624KN6GM2T
- CHEMBL1201182
- NCGC00167518-01
- Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]
- Temserolimus
- NSC-683864
- MFCD00934421
- Temsirolimus (CCI-779, NSC 683864)
- Temsirolimus [USAN]
- Temsirolimus - Torisel
- TEMSIROLIMUS [MI]
- TEMSIROLIMUS [INN]
- TEMSIROLIMUS [JAN]
- TEMSIROLIMUS [VANDF]
- UNII-624KN6GM2T
- SCHEMBL18792
- TEMSIROLIMUS [MART.]
- 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin
- TEMSIROLIMUS [WHO-DD]
- WAY-CCI 779
- GTPL5892
Reported adverse events
- Rash
- Acne
- Nausea
- Infection
- Stomatitis
- Azoospermia
- Hypersensitivity
- Pain
- Pneumonitis
- Constipation
- Headache
- Hypertension
Look up TEMSIROLIMUS in the interactive SynDRA portal →